Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/50105
Title: Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica
Authors: Naranjo, Antonio 
López, Rubén
García-Magallón, Blanca
Cáceres, Laura
Francisco, Félix
Jiménez-Palop, Mercedes
Ojeda-Bruno, Soledad
Keywords: Vertebral Fracture
Bone-Density
Double-Blind
Prevention
Risedronate, et al
Issue Date: 2014
Publisher: 0172-8172
Journal: Rheumatology International 
Abstract: The aim of this study was to analyze the longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica (PMR). Patients diagnosed with PMR were collected retrospectively in two rheumatology departments. In addition to demographic and diagnostic criteria, the chart review included the following information at baseline and at follow-up: doses of prednisone, prescription of calcium, vitamin D and bisphosphonates, bone mass measurement (BMD) and fragility fractures. We analyzed the percentage of patients undergoing BMD and were prescribed a bisphosphonate over the years. We evaluated 158 patients: 117 of them were women, mean age was 73 years, and they had an average follow-up of 4.8 years. 104 patients (66 %) received osteoporosis medication during the first visit, 44 of them were given bisphosphonate. During follow-up, another 30 treatments with bisphosphonate were added (46 % overall) while 37 cases (23 %) received no treatment with calcium or bisphosphonate. BMD was performed in 111 patients (69 %; 53 % of males and 76 % of females). Factors associated with the use of bisphosphonates were female sex (OR 4.4, 95 % CI 4.02-4.86), BMD (OR 2.4, 95 % CI 2.05-2.78) and commencement of treatment after the year 2005 (54 vs 37 %, OR 1.93, 95 % CI 1.60-2.26). No significant differences were found with age, initial doses of prednisone or the hospital. According to recent prevention guidelines, treatment with biphosphonate should have been administered in more than 90 % of patients. Although prophylaxis of glucocorticoid-induced osteoporosis in patients with PMR has increased in the recent years, many patients do not receive prophylaxis with bisphosphonate during the first visit.
URI: http://hdl.handle.net/10553/50105
ISSN: 0172-8172
DOI: 10.1007/s00296-014-3014-2
Source: Rheumatology International[ISSN 0172-8172],v. 34, p. 1459-1463
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

3
checked on May 9, 2021

WEB OF SCIENCETM
Citations

2
checked on May 9, 2021

Page view(s)

5
checked on May 15, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.